Wegovy maker Novo shares slump as management grilled on pricing, M&A

Wegovy maker Novo shares slump as management grilled on pricing, M&A — Live Feedhttps://www.live-feeds.com/feed/wegovy-maker-novo-shares-slump-as-management-grilled-on-pricing-m-aContinuously updated, source-cited coverage. Novo Nordisk Shares Slide as Strategy Fails to Quell Investor Doubtshttps://www.live-feeds.com/feed/wegovy-maker-novo-shares-slump-as-management-grilled-on-pricing-m-ahttps://www.live-feeds.com/feed/wegovy-maker-novo-shares-slump-as-management-grilled-on-pricing-m-a#u81350Wed, 23 Sep 2026 12:46:20 +0000Novo Nordisk shares slumped as management faced tough questions regarding pricing pressures, mergers and acquisitions, and its post-Wegovy growth strategy. Investors expressed dissatisfaction during briefings outlining direct-to-consumer operations and plans targeting obesity markets. Chief executive officials detailed ambitions to introduce more than five blockbuster medications by 2030 and target a specific revenue goal by 2035. Meanwhile, competitor Viking Therapeutics reported strong trial results for an experimental obesity treatment, driving its stock up significantly.Why it mattersThe p